GSK
GlaxoSmithKline eyes Indian deal
September 23, 2009Sales and Marketing GSK, India
GlaxoSmithKline is said to be looking to buy an Indian firm, according to reports in one of the country's largest …
GSK encouraged by first H1N1 vaccines results
September 15, 2009Sales and Marketing GSK, h1n1
Results from the first trial of GlaxoSmithKline's new pandemic swine flu vaccine have been revealed. A German study of 130 …
‘No shortcuts’ on H1N1 vaccine safety says GlaxoSmithKline
August 20, 2009Research and Development, Sales and Marketing GSK, h1n1, vaccines
GlaxoSmithKline says the public need not doubt the safety of its vaccine against the H1N1 swine flu, which it is …
GSK starts first trials for H1N1 vaccine in Germany
August 17, 2009Research and Development, Sales and Marketing GSK, h1n1, vaccines
GSK is to embark on the clinical development for its pandemic swine flu vaccine, completing enrolment into its first study …
Vernalis and GSK sign risk-sharing deal
August 7, 2009Research and Development, Sales and Marketing Deals, GSK, Vernalis
Vernalis and GlaxoSmithKline have joined forces to work on a cancer treatment in a deal which could be worth more …
GSK to co-market Amgen’s osteoporosis drug in Europe
July 28, 2009Sales and Marketing Amgen, Deals, GSK
GlaxoSmithKline has signed a major deal with Amgen to co-market its new osteoporosis treatment denosumab in Europe, Australia, New Zealand …
Manufacturing news in brief
July 27, 2009Manufacturing and Production GSK
Pharmafocus presents a round-up of developments in manufacturing, including facility updates from Takeda, Merrion Pharma, Cambridge Major, Dendreon and GlaxoSmithKline, …
Generic losses outweigh pandemic pluses for GSK
July 23, 2009Sales and Marketing GSK
GlaxoSmithKline has reported a 2% fall in sales for the second quarter as growing generic competition in the US bites. …
Lupus drug shows surprise phase III success
July 23, 2009Research and Development, Sales and Marketing Benlysta, GSK, HGS, Lupus
GSK and Human Genome Sciences’ lupus drug Benlysta has surprised analysts by showing unexpectedly positive results in a pivotal late-stage …
NICE to reconsider GSK’s Tyverb
July 9, 2009Research and Development, Sales and Marketing GSK, NICE, Tyverb
NICE is to reconsider Tyverb under its new lenient approach for end-of-life drugs, after GSK appealed its previous rejection of …
GSK signs arthritis drug development collaboration
June 25, 2009Research and Development, Sales and Marketing Deals, GSK
GlaxoSmithKline and Oxford-based Chroma Therapeutics are linking up to identify small molecule therapeutics in a bid to combat conditions like …
GSK to co-market generics with Dr. Reddy’s
June 17, 2009Sales and Marketing Dr Reddy, GSK, em, generics
GlaxoSmithKline will increase its reach into emerging markets with a new deal to co-market generics with Dr. Reddy’s.The Indian company …
Major Glaxo accounts go to TBWA
June 9, 2009Medical Communications, Sales and Marketing GSK
GlaxoSmithKline has chosen new agencies to handle some of it biggest consumer brands, including Nicorette and weight loss drug Alli. …
GSK signs oncology deal with UK biotech
May 18, 2009Research and Development, Sales and Marketing GSK, Oxford Biotherapeutics
GSK has struck a deal with Oxford BioTherapeutics to develop therapies for primary, metastatic and recurring forms of cancer. The …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
